Dr. Faramand is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
12902 Usf Magnolia Dr
Tampa, FL 33612Phone+1 703-517-0491
Education & Training
University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2016 - 2019
University of MarylandResidency, Internal Medicine, 2012 - 2015
Virginia Commonwealth University School of MedicineClass of 2012
Certifications & Licensure
FL State Medical License 2016 - 2026
MD State Medical License 2015 - 2016
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies Start of enrollment: 2022 Jun 21
Roles: Contact
- A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL Start of enrollment: 2022 Jan 14
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Intermediate-affinity CD19-directed CAR T cell product obecabtagene autoleucel demonstrates favourable safety and efficacy in R/R B-ALL.Rawan G Faramand, Frederick L Locke
Nature Reviews. Clinical Oncology. 2025-02-10 - 2 citationsOutcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.Gregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, Chenyu Lin, Simone E Dekker
Journal of Clinical Oncology. 2025-02-10 - Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Versus Younger Patients.Giacomo Adoncecchi, Ambuj Kumar, Krishnakar Mogili, Rawan Faramand, Hien Liu
Cancers. 2025-01-19
Abstracts/Posters
- Impact of TBI-Based Conditioning Regimen on Outcomes of Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant: Systematic Revi...Rawan Faramand, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Tumor Inflammation and Myeloid Derived Suppressor Cells Reduce the Efficacy of CD19 CAR T Cell Therapy in LymphomaRawan Faramand, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell TherapyRawan Faramand, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
- Moffitt Researchers Identify Factors to Predict Severe Toxicities in CAR T PatientsJuly 15th, 2020
Risk Stratification Can Predict Outcomes for CAR T-cell Therapy in LymphomaFebruary 16th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
